LumaFlo utilizes patent-pending nanotechnology that combines airflow and light to eliminate 99.997% of airborne pathogens. This technology addresses the inadequacies of current air purification systems, providing a robust solution for enhancing indoor air quality and reducing the risk of airborne diseases.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current air purification systems often fall short in effectively eliminating airborne pathogens, leaving individuals vulnerable to airborne diseases and compromising indoor air quality. Existing technologies may lack the robustness needed to combat a wide range of pathogens and emerging threats.
Solution
LumaFlo offers an advanced air decontamination solution leveraging patent-pending nanotechnology. This technology combines airflow and light to eliminate 99.997% of airborne pathogens. By utilizing this innovative approach, LumaFlo provides a robust defense against airborne diseases, significantly enhancing indoor air quality. The system's design focuses on efficiently capturing and neutralizing pathogens, creating a safer and healthier environment.
Target Audience
The primary target audience includes individuals and organizations concerned with maintaining high indoor air quality and reducing the risk of airborne disease transmission.
Features
- Nanotechnology-based air decontamination system
- Utilizes airflow and light for pathogen elimination
- Eliminates 99.997% of airborne pathogens